| Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF-kappaB pathways. | Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF-κB pathways.
Zhou J, Dong C, Tan J, Wang G, Li Z, Li S, He Z. | 02/8/2024 |
| Prognostic value of plasma secretoneurin concentration in patients with heart failure with reduced ejection fraction in one-year follow-up. | Prognostic value of plasma secretoneurin concentration in patients with heart failure with reduced ejection fraction in one-year follow-up.
Wołowiec Ł, Rogowicz D, Budzyński J, Banach J, Wołowiec A, Kozakiewicz M, Bieliński M, Jaśniak A, Osiak J, Grześk G., Free PMC Article | 02/5/2024 |
| Circulating secretoneurin level reflects angiographic coronary collateralization in stable angina patients with chronic total occlusion. | Circulating secretoneurin level reflects angiographic coronary collateralization in stable angina patients with chronic total occlusion.
Wu ZM, Huang K, Dai Y, Chen S, Wang XQ, Yang CD, Li LY, Liu JM, Lu L, Zhang RY, Shen WF, Shen Y, Ding FH., Free PMC Article | 01/10/2024 |
| [High expression of secretogranin II increases oxaliplatin resistance of colorectal cancer cells]. | [High expression of secretogranin II increases oxaliplatin resistance of colorectal cancer cells].
Deng J, Pan T, Zhou G, Gao Y, Peng W, Wei W, Lü C., Free PMC Article | 11/28/2023 |
| Investigation of secretoneurin as a potential biomarker of brain injury in very preterm infants: A pilot study. | Investigation of secretoneurin as a potential biomarker of brain injury in very preterm infants: A pilot study.
Posod A, Wechselberger K, Pellkofer Y, Hammerl M, Urbanek M, Huber E, Kiechl-Kohlendorfer U, Griesmaier E., Free PMC Article | 04/12/2023 |
| SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer. | SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer.
Weng S, Liu Z, Ren X, Xu H, Ge X, Ren Y, Zhang Y, Dang Q, Liu L, Guo C, Beatson R, Deng J, Han X., Free PMC Article | 07/30/2022 |
| AGTR1, PLTP, and SCG2 associated with immune genes and immune cell infiltration in calcific aortic valve stenosis: analysis from integrated bioinformatics and machine learning. | AGTR1, PLTP, and SCG2 associated with immune genes and immune cell infiltration in calcific aortic valve stenosis: analysis from integrated bioinformatics and machine learning.
Jiang C, Jiang W. | 04/23/2022 |
| Secretogranin II impairs tumor growth and angiogenesis by promoting degradation of hypoxia-inducible factor-1alpha in colorectal cancer. | Secretogranin II impairs tumor growth and angiogenesis by promoting degradation of hypoxia-inducible factor-1α in colorectal cancer.
Fang C, Dai L, Wang C, Fan C, Yu Y, Yang L, Deng H, Zhou Z., Free PMC Article | 04/16/2022 |
| Nanoplasmonic immunosensor for the detection of SCG2, a candidate serum biomarker for the early diagnosis of neurodevelopmental disorder. | Nanoplasmonic immunosensor for the detection of SCG2, a candidate serum biomarker for the early diagnosis of neurodevelopmental disorder.
Lim SH, Sung YJ, Jo N, Lee NY, Kim KS, Lee DY, Kim NS, Lee J, Byun JY, Shin YB, Lee JR., Free PMC Article | 02/5/2022 |
| serum levels of CgA, CgB, and SgII were determined in Parkinson's disease patients and assessed their association with disease severity. | Serum levels of chromogranins and secretogranins correlate with the progress and severity of Parkinson's disease.
Xu DJ, Wei LY, Li HF, Zhang WQ. | 08/10/2019 |
| Differential Reovirus-Specific and Herpesvirus-Specific Activator Protein 1 Activation of Secretogranin II Leads to Altered Virus Secretion. | Differential Reovirus-Specific and Herpesvirus-Specific Activator Protein 1 Activation of Secretogranin II Leads to Altered Virus Secretion.
Berard AR, Severini A, Coombs KM., Free PMC Article | 03/5/2016 |
| present data show that SgII is highly expressed in advanced prostate cancer and may contribute to the neuroendocrine differentiation by promoting the formation of secretory granules and the proliferation of PCa cells. | Secretogranin II is overexpressed in advanced prostate cancer and promotes the neuroendocrine differentiation of prostate cancer cells.
Courel M, El Yamani FZ, Alexandre D, El Fatemi H, Delestre C, Montero-Hadjadje M, Tazi F, Amarti A, Magoul R, Chartrel N, Anouar Y. | 01/24/2015 |
| SN induces MUC5AC hypersecretion in a dose- and time-dependent manner; moreover, the MUC5AC over synthesis induced by SN is strongly associated with the enhanced binding of EGF to NRP1 | Secretoneurin induces airway mucus hypersecretion by enhancing the binding of EGF to NRP1.
Xu R, Li Q, Zhou J, Zhou X, Perelman JM, Kolosov VP. | 10/18/2014 |
| Topical secretoneurin gene therapy accelerates diabetic wound healing by interaction between heparan-sulfate proteoglycans and basic FGF. | Topical secretoneurin gene therapy accelerates diabetic wound healing by interaction between heparan-sulfate proteoglycans and basic FGF.
Albrecht-Schgoer K, Schgoer W, Theurl M, Stanzl U, Lener D, Dejaco D, Zelger B, Franz WM, Kirchmair R. | 08/23/2014 |
| Manserin may serve as a marker of prostate cancer progression. | Manserin as a novel histochemical neuroendocrine marker in prostate cancer.
Nishikawa K, Soga N, Ishii K, Kato M, Iwamoto Y, Hori Y, Etoh M, Ohkawara T, Yamada T, Uchida K, Kise H, Arima K, Narita M, Shiraishi T, Sugimura Y. | 04/26/2014 |
| CgA, CgB, and secretoneurin are detectable in feces, and collagenous colitis patients express higher values than patients with inflammatory bowel disease and controls. In treatment, fecal secretoneurin decreased to control levels in collagenous colitis. | Increased fecal levels of chromogranin A, chromogranin B, and secretoneurin in collagenous colitis.
Wagner M, Stridsberg M, Peterson CG, Sangfelt P, Lampinen M, Carlson M. | 03/22/2014 |
| In vivo secretoneurin improves left ventricular function, inhibits remodeling, and reduces scar formation; in the infarct border zone, secretoneurin induces coronary angiogenesis. | The angiogenic factor secretoneurin induces coronary angiogenesis in a model of myocardial infarction by stimulation of vascular endothelial growth factor signaling in endothelial cells.
Albrecht-Schgoer K, Schgoer W, Holfeld J, Theurl M, Wiedemann D, Steger C, Gupta R, Semsroth S, Fischer-Colbrie R, Beer AG, Stanzl U, Huber E, Misener S, Dejaco D, Kishore R, Pachinger O, Grimm M, Bonaros N, Kirchmair R., Free PMC Article | 01/26/2013 |
| Circulating Levels of SgII are Increased in Patients with chronic, stable heart failure. | Secretogranin II; a protein increased in the myocardium and circulation in heart failure with cardioprotective properties.
Røsjø H, Stridsberg M, Florholmen G, Stensløkken KO, Ottesen AH, Sjaastad I, Husberg C, Dahl MB, Øie E, Louch WE, Omland T, Christensen G., Free PMC Article | 09/29/2012 |
| Data describe the gene expression and protein production of SgII in normal adrenal glands and pheochromocytomas with the goal to examine the molecular mechanisms leading to the marked variations in the expression of EM66 in tumoral chromaffin tissue. | Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.
Guillemot J, Thouënnon E, Guérin M, Vallet-Erdtmann V, Ravni A, Montéro-Hadjadje M, Lefebvre H, Klein M, Muresan M, Seidah NG, Anouar Y, Yon L. | 06/9/2012 |
| This short review deals with investigations in neuroendocrine tumors (NETs) with antibodies against defined epitopes of chromogranins (Cgs) A and B and secretogranins (Sgs) II and III. | Immunohistochemical and biochemical studies with region-specific antibodies to chromogranins A and B and secretogranins II and III in neuroendocrine tumors.
Portela-Gomes GM, Grimelius L, Stridsberg M. | 04/16/2011 |
| More SgII immunoreactive cells were observed in phaeochromocytomas. | Secretogranin III in human neuroendocrine tumours: a comparative immunohistochemical study with chromogranins A and B and secretogranin II.
Portela-Gomes GM, Grimelius L, Stridsberg M. | 04/16/2011 |
| semiquantitative immunocytochemistry for secretogranin II in amyotrophic lateral sclerosis. | Chromogranin peptides in amyotrophic lateral sclerosis.
Schrott-Fischer A, Bitsche M, Humpel C, Walcher C, Maier H, Jellinger K, Rabl W, Glueckert R, Marksteiner J. | 01/21/2010 |
| Suppression of Pdcd4 resulted in an increased release of CgA and Sg II and was accompanied by an up-regulation of intracellular PC1. | Knockdown of Pdcd4 results in induction of proprotein convertase 1/3 and potent secretion of chromogranin A and secretogranin II in a neuroendocrine cell line.
Lankat-Buttgereit B, Müller S, Schmidt H, Parhofer KG, Gress TM, Göke R. | 01/21/2010 |
| Increased concentrations of SgII, especially the N-terminal part of secretoneurin could be measured in plasma from patients with endocrine pancreatic tumours. | Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours.
Stridsberg M, Eriksson B, Janson ET. | 01/21/2010 |
| Results suggest that secretogranin II represents a key AP-1-regulated protein that counteracts nitric oxide toxicity and mediates neuronal differentiation of neuroblastoma cells. | Secretogranin II: a key AP-1-regulated protein that mediates neuronal differentiation and protection from nitric oxide-induced apoptosis of neuroblastoma cells.
Li L, Hung AC, Porter AG. | 01/21/2010 |